One month ago, Oncodesign Services announced the acquisition of ZoBio, a Dutch CRO specialized in Small Molecule Drug Discovery
2 companies, 1 promise: accelerating discoveries and developing innovative treatments! Follow our exciting story and stay tuned to witness the positive impact this union can have on research…
Watch the interview of Fabrice Viviano, CEO of Oncodesign Services, and Gregg Siegal, CEO of ZoBio :
Oncodesign Services (ODS) is a leading CRO specializing in drug discovery and preclinical services. It contributes to the development of innovative therapies in oncology, inflammation and infectious diseases, through integrated capabilities in medicinal chemistry, DMPK, pharmaco-imaging, bioanalysis, and in vivo/in vitro pharmacology. Oncodesign Services has 230 employees in France and Canada.
More information: www.oncodesign-services.com
ZoBio has built a class-leading platform that provides a complete solution for Fragment Based Drug Discovery to our clients. Our gene-to-lead capabilities include: protein production, biophysical and functional assays, structural biology (crystallography, NMR & cryoEM) and fragment focused medicinal chemistry. Our team of 46 people brings its dedication and expertise to help solve your largest drug discovery challenges.
More information: https://www.zobio.com